UBS Group
KPTI icon

UBS Group’s Karyopharm Therapeutics KPTI Stock Holding History

UBS Group’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,820
Closed -$423K – 9257
2020
Q4 		$423K Buy
+1,820
New +$422K ﹤0.01% 4728

Other funds holding KPTI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

UBS Group's KPTI Position: Q2 2026 in Review

UBS Group increased its Karyopharm Therapeutics (KPTI) stake by 82% in Q2 2026, buying an estimated $1.38M and bringing the position to 353,545 shares worth $3.45M. The position accounts for ﹤0.01% of the portfolio, ranked #4560.

UBS Group first reported a position in KPTI in Q4 2014 and has held it in 47 quarters since. The position peaked at $6.95M in Q4 2014. 96 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • UBS Group held 353,545 shares of Karyopharm Therapeutics worth $3.45M as of Q2 2026.
  • UBS Group bought 159,528 Karyopharm Therapeutics shares in Q2 2026, an estimated $1.38M.
  • Karyopharm Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4560 holding.
  • UBS Group first reported a position in Karyopharm Therapeutics in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Karyopharm Therapeutics position peaked at $6.95M in Q4 2014.
  • 96 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.